Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/21933857http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/21933857http://www.w3.org/2000/01/rdf-schema#comment"

Background

Congenital secondary erythrocytoses are due to deregulation of hypoxia inducible factor resulting in overproduction of erythropoietin. The most common germline mutation identified in the hypoxia signaling pathway is the Arginine 200-Tryptophan mutant of the von Hippel-Lindau tumor suppressor gene, resulting in Chuvash polycythemia. This mutant displays a weak deficiency in hypoxia inducible factor α regulation and does not promote tumorigenesis. Other von Hippel-Lindau mutants with more deleterious effects are responsible for von Hippel-Lindau disease, which is characterized by the development of multiple tumors. Recently, a few mutations in gene for the prolyl hydroxylase domain 2 protein (PHD2) have been reported in cases of congenital erythrocytosis not associated with tumor formation with the exception of one patient with a recurrent extra-adrenal paraganglioma.

Design and methods

Five PHD2 variants, four of which were novel, were identified in patients with erythrocytosis. These PHD2 variants were functionally analyzed and compared with the PHD2 mutant previously identified in a patient with polycythemia and paraganglioma. The capacity of PHD2 to regulate the activity, stability and hydroxylation of hypoxia inducible factor α was assessed using hypoxia-inducible reporter gene, one-hybrid and in vitro hydroxylation assays, respectively.

Results

This functional comparative study showed that two categories of PHD2 mutants could be distinguished: one category with a weak deficiency in hypoxia inducible factor α regulation and a second one with a deleterious effect; the mutant implicated in tumor occurrence belongs to the second category.

Conclusions

As observed with germline von Hippel-Lindau mutations, there are functional differences between the PHD2 mutants with regards to hypoxia inducible factor regulation. PHD2 mutation carriers do, therefore, need careful medical follow-up, since some mutations must be considered as potential candidates for tumor predisposition."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.org/dc/terms/identifier"doi:10.3324/haematol.2011.044644"xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Richard S."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Pouyssegur J."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Hermine O."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Hoogewijs D."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Wenger R.H."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Feunteun J."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Gimenez-Roqueplo A.P."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Bressac-de Paillerets B."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Gad S."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Mazure N."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Barrois M."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Casadevall N."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Leporrier M."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Baruchel A."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Gardie B."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Carcenac R."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Kiladjian J.J."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Ladroue C."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Fakhoury F."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/author"Storti F."xsd:string
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/date"2012"xsd:gYear
http://purl.uniprot.org/citations/21933857http://purl.uniprot.org/core/name"Haematologica"xsd:string
▶